Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TPMT | P51580 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179149 | 0.84 | TPMT (0.56) | SMN1; SMN2ALDH1A1MAPK1TPMTALOX15 | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL56204 | 0.84 | TPMT (0.56) | SMN1; SMN2ALDH1A1MAPK1TPMTALOX15 | |
| SCHEMBL4928556 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPK1LMNANPC1 | |
| SCHEMBL29561847 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPK1LMNANPC1 | |
| SCHEMBL348783 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPK1LMNAGPBAR1 | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL7828838 | 0.82 | TPMT (0.54) | SMN1; SMN2ALDH1A1MAPK1TPMTALOX15 | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL11071500 | 0.82 | TPMT (0.54) | SMN1; SMN2ALDH1A1MAPK1TPMTALOX15 | |
| Hydrochloric Acid SCHEMBL1179035 | 0.82 | TPMT (0.54) | SMN1; SMN2ALDH1A1MAPK1TPMTALOX15 | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL2264628 | 0.82 | TPMT (0.54) | SMN1; SMN2ALDH1A1MAPK1TPMTALOX15 | |
| Hydrochloric Acid SCHEMBL11078337 | 0.82 | TPMT (0.54) | SMN1; SMN2ALDH1A1MAPK1TPMTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775201-A | 2-Methoxy-4-amino-6-methylpyridine and synthetic method thereof | 上海毕得医药科技股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2026105052-A1 | BIARYL ACID COMPOUNDS | PFIZER INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260138982-A1 | Biaryl Acid Compounds | PFIZER INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12514858-B2 | CD38 inhibitors | Astellas Engineered Small Molecules US, Incorporated (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4646402-A1 | GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2025-11-12 | — | — | EP | disclosed |
| EP-4643954-A2 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-0944388-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999026924-A1 | SUBSTITUTED OXIMES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5891889-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-04-06 | — | — | US | disclosed |
| CN-1205694-A | Quinazoline derivatives | ZENECA LTD (GB) | 1999-01-20 | — | — | CN | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998033772-A1 | 2-METHOXYIMINO-2-(PYRIDINYLOXYMETHYL)PHENYL ACETAMIDES WITH CARBOXYLIC ACID DERIVATIVES ON THE PYRIDINE RING AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138982-A1 | Biaryl Acid Compounds | PIK3R1, PIK3R3, PIK3R5 | SMN1; SMN2 3439/4885ALDH1A1 2773/4885MAPK1 186/4885 |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | SMN1; SMN2 3525/4885ALDH1A1 3836/4885MAPK1 3611/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | SMN1; SMN2 2967/4885ALDH1A1 3280/4885MAPK1 458/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | SMN1; SMN2 2897/4885ALDH1A1 232/4885MAPK1 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.